Our strategy was pretreatment by Rad51-inhibitory substances by intravenous low-dose gemcitabine followed by arterial administration of antineoplastic agents causing DNA, DSB, or DNA crosslink, which might be more beneficial for patients with locally advanced pancreatic cancers than other treatments previously reported. The gene discussed is RAD51; the disease is familial pancreatic carcinoma.